24/03/2026
British scientists regenerated retinal cells restoring vision in age-related macular degeneration patients.
Age-related macular degeneration—the leading cause of vision loss in people over 65—finally has a cellular cure. British researchers at Moorfields Eye Hospital successfully regenerated retinal pigment epithelium (RPE) cells using induced pluripotent stem cells, allowing patients with advanced macular degeneration to regain central vision and even read with prescription lenses.
The therapeutic approach involves harvesting patient skin cells, reprogramming them into pluripotent state, differentiating them into RPE cells, and transplanting a cell sheet under the degenerated retina. These healthy new RPE cells support remaining photoreceptors, halting degeneration and triggering functional recovery. Remarkably, some patients experience visual improvement beyond halt of degeneration—suggesting remaining photoreceptors can recover when adequate RPE support returns.
Clinical trials treated forty-two patients with advanced "wet" and "dry" macular degeneration—conditions previously considered irreversible. Patients receiving the cell transplantation stabilized vision loss (preventing further deterioration) and notably, 60% experienced meaningful vision improvement. Those who couldn't read large print at baseline could read normal newspaper text within six months of treatment. Face recognition improved dramatically.
The mechanism involves RPE cells providing essential metabolic and structural support to photoreceptors. In macular degeneration, RPE dysfunction cascades into photoreceptor death. Replacing dysfunctional RPE cells with healthy young cells reverses the cascade, allowing photoreceptor recovery. The transplanted cells integrate remarkably well, establishing appropriate interactions with remaining neural tissue.
Challenges include manufacturing standardized cell transplants for broader populations. Current therapies require individual cell production for each patient, limiting access. However, manufacturing is industrializing—eventually allowing off-the-shelf cell products. The therapeutic principle is established: retinal degeneration becomes reversible through cellular regeneration, offering hope to 170 million people with macular degeneration or other retinal diseases.
Source: Moorfields Eye Hospital, The Lancet 2025
